Draegerwerk AG & Co. KGaA DRW8
XETR · Germany · Health Technology
€90.40-1.20 (-1.31%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Strong sales growth and a tripling of EBIT drive optimism, though geopolitical tensions and a medical division decline pose challenges.
Drägerwerk AG & Co. KGaA (ETR:DRW3) reported higher sales, sharply improved earnings and a return to positive free cash flow in the first half of 2026, supported by demand across its safety business, improved gross margins and customs refunds recognized during the second quarter. Chief Executiv
Drägerwerk AG & Co. KGaA (ETR:DRW3) reported higher order intake, revenue growth, and a sharp improvement in earnings in the first quarter of 2026, supported by strong demand in its medical business and improving profitability in its safety division. CEO Stefan Dräger described the period as “a
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.